Company / Cash & Equivalents
CRISPR Therapeutics AG Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$347.6M
FY2025
5-year range
$211.9M / $923.0M
FY2021-FY2025
Trend
+16.5%
vs FY2024
Sector context
#59 of 209
Health Care
What the data says
At $348M, CRISPR Therapeutics AG's cash & equivalents ranks #59 of 209 in the Health Care sector. Cash & Equivalents has fluctuated over the past 10 years, ranging from $212M in FY2022 to $1.2B in FY2020.
Based on SEC 10-K filings.
$348M in FY2025 with a 5-year CAGR of -21.5%.
Declined from $389M to $348M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +17.9%
- 5-Year CAGR
- -21.5%
- 10-Year CAGR
- -
Sector benchmark
#59 of 209 in Health CareTop 28% of 209This company $347.6M Sector average $696.0M
▼
-50.1% below sector average
Key checks
Key Insights
- 5-year CAGR of -21.5%, indicating a declining trend.
- In FY2025, cash & equivalents increased 16.5% year-over-year.
- Ranks #59 out of 209 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $347.6M | +16.5% |
| FY2024 | $298.3M | -23.4% |
| FY2023 | $389.5M | +83.8% |
| FY2022 | $211.9M | -77.0% |
| FY2021 | $923.0M | -21.0% |
| FY2020 | $1.2B | +23.8% |
| FY2019 | $943.8M | +106.7% |
| FY2018 | $456.6M | +90.5% |
| FY2017 | $239.8M | -24.0% |
| FY2016 | $315.5M | +102.3% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026